市場調查報告書

攝護腺特異性抗原 (PSA) 檢驗的全球市場:各類型、各化驗、各地區的未來預測

Prostate Specific Antigen (PSA) Testing Market - Forecast (2020 - 2025)

出版商 IndustryARC 商品編碼 850039
出版日期 內容資訊 英文 105 Pages
商品交期: 2-3個工作天內
價格
攝護腺特異性抗原 (PSA) 檢驗的全球市場:各類型、各化驗、各地區的未來預測 Prostate Specific Antigen (PSA) Testing Market - Forecast (2020 - 2025)
出版日期: 2020年03月11日內容資訊: 英文 105 Pages
簡介

本報告提供全球攝護腺特異性抗原 (PSA) 檢驗的市場相關分析,整體市場結構,及主要推動及阻礙市場要素,市場競爭概況,近來的資本交易、策略展開的動向,各類型、各地區的市場趨勢預測 (今後6年份),主要企業的簡介等的相關調查。

第1章 攝護腺特異性抗原 (PSA) 檢驗:市場概要

第2章 摘要整理

第3章 PSA檢驗:市場環境

  • 市場佔有率分析
  • 比較分析
    • 產品的互相比較
    • 終端用戶的分析
    • 專利分析
    • 前五名公司的財務分析

第4章 PSA檢驗:對市場的影響要素

  • 推動市場要素
  • 市場課題
  • 市場風險要素
  • 產業的吸引力:波特的五力分析

第5章 PSA檢驗市場:策略分析

  • 價值鏈分析
  • 市場機會分析
  • 產品/市場生命週期分析

第6章 PSA檢驗市場:各類型

  • 自由PSA檢驗
  • 複合型PSA檢驗
  • RT-PCR (逆轉錄聚合酵素鏈鎖反應) 法的PSA檢驗

第7章 全球PSA檢驗市場:各地區的分析

  • 簡介
  • 北美 (加拿大,美國)
  • 歐洲
  • 亞太地區
  • 其他的國家 (RoW)

第8章 市場最新形勢

  • 新產品的銷售
  • 企業合併、收購 (M&A),事業合作/聯盟,合資企業

第9章 企業簡介 (概要,財務分析,SWOT分析 (前五名公司的情況),近幾年趨勢,產品系列)

  • Abbott Laboratories, Inc.
  • Bayer AG
  • Beckman Coulter, Inc.
  • GE Helathcare
  • GlaxoSmithKline, plc.
  • Novartis Pharma AG.
  • UroLogix, Inc.
  • Bristol - Myers Squibb Company
  • AstraZeneca plc.
  • Johnson & Johnson Diagnostics
  • BioChem Pharma
  • Pharmacia Delfia
  • Roche Diagnostics
  • Olympus
  • Tosoh

第10章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: HCR 0038

Prostate Specific Antigen (PSA) Testing Market Overview:

The global prostate-specific antigen testing market is primarily progressing growth because of the rise in prostate cancer among men, who are over 50 years in age. Furthermore, the adoption of various assay based methods and various new inventions for the diagnosis of prostate cancer has raised the demand for PSA testing. The combination of advanced technology for PSA testing has improved the accuracy and specificity of the results playing an important role in boosting the market. Europe contributes for a huge revenue market share for prostate specific antigen testing, accounting for nearly 45% of the global revenue. The market for prostate specific antigen testing in 2017 was $ 2264.84 million and is expected to reach $ 2774.12 million by 2023 at an estimated CAGR of 4.14% during forecast period of 2018-2023

Prostate Specific Antigen (PSA) Testing Market Outlook:

Prostate-specific antigen (PSA) is a type of glycoprotein secreted by epithelial prostatic cells. There are two forms of PSA that circulates freely through the body, either bound to other cells or on their own. The higher levels of the PSA indicate a higher chances of being affected by Prostate cancer. The PSA levels are measured by conducting tests such as Total prostate Specific Antigen Test (tPSA), Free Prostate Specific Antigen Test (fPSA), Complex Prostate Specific Antigen Test (cPSA), Prostate Specific Antigen Reverse Transcription Polymerase chain reaction test (PSA-RT PCR) and so on. In addition to these tests there are some assays for identification of the PSA levels such as Radioimmunoassay (RIA), Enzyme Immunoassay (EIA), PCA3Test, Trans-rectal Ultrasound, Biopsy and other tests. Further tests for Density of PSA and Velocity of PSA were identified, but had no such significance and acceptance.

Prostate specific Antigen Testing Market report comprises of pricing analysis for different types of PSA tests conducted segmented geographically. Europe accounted for price of $47.5 for PSA testing in 2017 and estimated to be $46.16 by 2022. Europe region has the highest prices for PSA Testing in 2017 and is also estimated to have the same in 2022 as well.

Prostate Specific Antigen (PSA) Testing Market Growth drivers:

Prostate specific antigen testing market is driving ahead because of the increase in geriatric population. Also, the increased public awareness about the benefits of the Prostate cancer screening, Technological advancements in testing and treating the Prostate cancer, Several Reimbursement policies for the prostate cancer treatments in various developed and developing regions are affecting the growth of Prostate specific antigen market. According to U.S. Census Bureau's 2017 National Population Projections. By 2030, all baby boomers will be older than 65 so that 1 in every 5 residents will be in his or her retirement age. This indicates the growth in the size of geriatric population.

Prostate Specific Antigen (PSA) Testing Market Challenges:

Prostate specific antigen testing market need to face some hard situations because of the False-positive or False-negative results of PSA test. Also most of these tests like PSA Screening had a lot of side effects such as difficulties in flow of urine, effects on functioning of bowel, erectile dysfunction and frequent pains along with the false results, thereby hindering the growth of Prostate specific antigen testing market. Higher improvements in the technology resulting in most simplified and accurate results in the tests like Prostate Health Index (phi) can reduce the growth in PSA testing market unless there is a change in the way the tests are treated.

Prostate Specific Antigen (PSA) Testing Market Research Scope:

The base year of the study is 2017, with forecast done up to 2023. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. These provide the key market participants with the necessary business intelligence and help them understand the future of the Prostate specific antigen testing market. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, product and pricing analysis. The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats. The key areas of focus include the types of PSA tests in the Prostate specific antigen testing market, and their complete details including their forecast.

Prostate Specific Antigen (PSA) Testing Market Report: Industry Coverage

Prostate Specific Antigen Testing Market - By Tests type: Total Prostate Specific Antigen Test (tPSA), Complex Prostate Specific Antigen Test (cPSA), Free Prostate Specific Antigen Test (fPSA), Prostate Specific Antigen Reverse Transcription Polymerase Chain Reaction Test (PSA RT-PCR), PCA3Test, Trans-rectal Ultrasound, Biopsy.

Prostate Specific Antigen Testing Market - By Assays type: Radioimmunoassay (RIA), Enzyme Immunoassay (EIA).

The Prostate specific antigen testing market report also analyzes the major geographic regions for the market as well as the major countries for the market in these regions. The regions and countries covered in the study include:

North America: The U.S., Canada, Mexico

South America: Brazil, Venezuela, Argentina, Ecuador, Peru, Colombia, Costa Rica

Europe: The U.K., Germany, Italy, France, The Netherlands, Belgium, Spain, Denmark

APAC: China, Japan, Australia, South Korea, India, Taiwan, Malaysia, Hong Kong

Middle East and Africa: Israel, South Africa, Saudi Arabia

Prostate Specific Antigen (PSA) Testing Market Key Players Perspective:

Some of the Key players in this market that have been studied for this report include:

Abbott Laboratories, Inc., Bayer AG., Beckman Coulter, Inc., GE Healthcare, GlaxoSmithKline, plc., Novartis Pharma AG., UroLogix, Inc., Bristol - Myers Squibb Company, AstraZeneca plc. and so on.

Market Research and Market Trends of Prostate Specific Antigen (PSA) Testing Market

A new test named Gallium-68 PSMA PET Scan has been came into light for locating the recurrence of prostate cancer in the patients. This scan evaluates the prostate cancer recurrence with PSA level of less than 2 ng/dl (Nanogram per Decilitre). This imaging helps in reducing the clinical risk after certain Radical procedures and biopsies.

Diagnostic performance for prostate cancer is highly depended on the measurement of PSA ratio in clinical serum in the zone between 4.0 to 10.0 ng/Ml. Simultaneous detection of dual prostate specific antigens using Surface-Enhanced Raman Scattering-Based Immunoassay helps in diagnosing the prostate cancer more accurately.

Prostate specific antigen testing is good in sensitivity but low in specificity resulting in false results and further biopsies which are not even required. After certain research identification of new reliable assay to measure Glypican-1 in plasma and serum using biomarkers has been taken place to improve detection of prostate cancer. Being a novel prostate cancer biomarker, its impact on improvement of treatments would be higher than before.

A new assay named PSA Glycomics Assay reveals multiple glycoforms of PSA in urinary extract, including sialic acid linkage isomers as well the level of (core-)fucosylation. As per Cure for Cancer Foundation, Astellas Pharma B.V., the European Union and SCIEX. , Using this high performance PGA, evaluation of PSA glycosylation is possible for early detetion of Prostate Cancers

1. Prostate Specific Antigen Testing Market - Overview

  • 1.1. Definitions and Scope

2. Prostate Specific Antigen Testing Market - Executive summary

  • 2.1. Market Revenue, Market Size and Key Trends by Company
  • 2.2. Key Trends by type of Application
  • 2.3. Key Trends segmented by Geography

3. Prostate Specific Antigen Testing Market

  • 3.1. Comparative analysis
    • 3.1.1. Product Benchmarking - Top 10 companies
    • 3.1.2. Top 5 Financials Analysis
    • 3.1.3. Market Value split by Top 10 companies
    • 3.1.4. Patent Analysis - Top 10 companies
    • 3.1.5. Pricing Analysis

4. Prostate Specific Antigen Testing Market Forces

  • 4.1. Drivers
  • 4.2. Constraints
  • 4.3. Challenges
  • 4.4. Porters five force model
    • 4.4.1. Bargaining power of suppliers
    • 4.4.2. Bargaining powers of customers
    • 4.4.3. Threat of new entrants
    • 4.4.4. Rivalry among existing players
    • 4.4.5. Threat of substitutes

5. Prostate Specific Antigen Testing Market -Strategic analysis

  • 5.1. Value chain analysis
  • 5.2. Opportunities analysis
  • 5.3. Product life cycle

6. Prostate Specific Antigen Testing Market- By Test type (Market Size -$Million / $Billion)

  • 6.1. Market Size and Market Share Analysis
  • 6.2. Service Revenue and Trends by type of test
  • 6.3. Service Segment Analysis by test type
    • 6.3.1. Preliminary tests
      • 6.3.1.1. Total Prostate Specific Antigen Test
      • 6.3.1.2. Complex Prostate Specific Antigen Test
      • 6.3.1.3. Free Prostate Specific Antigen Test
      • 6.3.1.4. Prostate Specific Antigen Reverse Transcription Polymerase Chain Reaction Test
    • 6.3.2. Confirmatory tests
      • 6.3.2.1. PCA3Test
      • 6.3.2.2. Trans-rectal Ultrasound
      • 6.3.2.3. Biopsy

5. Prostate Specific Antigen Testing Market- By Assays type (Market Size -$Million / $Billion)

  • 5.1. Radioimmunoassay (RIA)
  • 5.2. Enzyme Immunoassay (EIA)

6. Prostate Specific Antigen Testing Market- By Geography (Market Size -$Million / $Billion)

  • 6.1. Prostate Specific Antigen Testing Market - North America Segment Research
  • 6.2. North America Market Research (Million / $Billion)
    • 6.2.1. Segment type Size and Market Size Analysis
    • 6.2.2. Revenue and Trends
    • 6.2.3. Application Revenue and Trends by type of Application
    • 6.2.4. Company Revenue and Product Analysis
    • 6.2.5. North America Product type and Application Market Size
      • 6.2.5.1. U.S.
      • 6.2.5.2. Canada
      • 6.2.5.3. Mexico
      • 6.2.5.4. Rest of North America
  • 6.3. Prostate Specific Antigen Testing Market- South America Segment Research
  • 6.4. South America Market Research (Market Size -$Million / $Billion)
    • 6.4.1. Segment type Size and Market Size Analysis
    • 6.4.2. Revenue and Trends
    • 6.4.3. Application Revenue and Trends by type of Application
    • 6.4.4. Company Revenue and Product Analysis
    • 6.4.5. South America Product type and Application Market Size
      • 6.4.5.1. Brazil
      • 6.4.5.2. Venezuela
      • 6.4.5.3. Argentina
      • 6.4.5.4. Ecuador
      • 6.4.5.5. Peru
      • 6.4.5.4. Colombia
      • 6.4.5.5. Costa Rica
      • 6.4.5.6. Rest of South America
  • 6.5. Prostate Specific Antigen Testing Market- Europe Segment Research
  • 6.4. Europe Market Research (Market Size -$Million / $Billion)
    • 6.4.1. Segment type Size and Market Size Analysis
    • 6.4.2. Revenue and Trends
    • 6.4.3. Application Revenue and Trends by type of Application
    • 6.4.4. Company Revenue and Product Analysis
    • 6.4.5. Europe Segment Product type and Application Market Size
      • 6.4.5.1. U.K
      • 6.4.5.2. Germany
      • 6.4.5.3. Italy
      • 6.4.5.4. France
      • 6.4.5.5. Netherlands
      • 6.4.5.4. Belgium
      • 6.4.5.5. Spain
      • 6.4.5.6. Denmark
      • 6.4.5.5. Rest of Europe
  • 6.5. Prostate Specific Antigen Testing Market- APAC Segment Research
  • 6.6. APAC Market Research (Market Size -$Million / $Billion)
    • 6.6.1. Segment type Size and Market Size Analysis
    • 6.6.2. Revenue and Trends
    • 6.6.3. Application Revenue and Trends by type of Application
    • 6.6.4. Company Revenue and Product Analysis
    • 6.6.5. APAC Segment - Product type and Application Market Size
      • 6.6.5.1. China
      • 6.6.5.2. Australia
      • 6.6.5.3. Japan
      • 6.6.5.4. South Korea
      • 6.6.5.5. India
      • 6.6.5.4. Taiwan
      • 6.6.5.5. Malaysia
      • 6.6.5.6. Hong Kong
      • 6.6.5.5. Rest of APAC
  • 6.5. Prostate Specific Antigen Testing Market- Middle East Segment and Africa Segment Research
  • 6.10. Middle East & Africa Market Research (Market Size -$Million / $Billion)
    • 6.10.1. Segment type Size and Market Size Analysis
    • 6.10.2. Revenue and Trend Analysis
    • 6.10.3. Application Revenue and Trends by type of Application
    • 6.10.4. Company Revenue and Product Analysis
    • 6.10.5. Middle East Segment Product type and Application Market Size
      • 6.10.5.1. Israel
      • 6.10.5.2. Saudi Arabia
      • 6.10.5.3. UAE
    • 6.10.4. Africa Segment Analysis
      • 6.10.4.1. South Africa
      • 6.10.4.2. Rest of Middle East & Africa

7. Prostate Specific Antigen Testing Market - Entropy

  • 7.1. New product launches
  • 7.2. M&A's, collaborations, JVs and partnerships

8. Prostate Specific Antigen Testing Market Company Analysis

  • 8.1. Market Share, Company Revenue, Products, M&A, Developments
  • 8.2. Abbott Laboratories Inc.
  • 8.3. Bayer AG.
  • 8.4. Beckman Coulter Inc.
  • 8.5. GE Healthcare
  • 8.4. GlaxoSmithKline plc.
  • 8.5. Novartis Pharma AG.
  • 8.6. UroLogix Inc.
  • 8.5. Bristol - Myers Squibb Company
  • 8.10. AstraZeneca plc.
  • 8.11. Company 10
  • 8.12. Company 11
  • 8.13. Company 12 and more

"*Financials would be provided on a best efforts basis for private companies"

9. Prostate Specific Antigen Testing Market -Appendix

  • 9.1. Abbreviations
  • 9.2. Sources